ABBVON

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Ime in priimek ABBVON

Uvrstitev No.3312

Tržna kapitalizacija $0.00

Popolnoma razredčena tržna kapitalizacija $0.00

Tržni delež %

Volumen trgovanja/tržna kapitalizacija (24h) 850,245.94%

Razpoložljivi obtok 123.08541488

Največja ponudba 0

Skupna ponudba 123.08541488

Hitrost kroženja %

Datum izdaje --

Cena, po kateri je bilo sredstvo prvič izdano --

Najvišja vrednost vseh časov 237.64005999136555, 2026-03-05

Najnižja cena 193.3720963640878, 2026-04-29

Javna veriga blokov ABBVON

Uvod AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Panoga

Družbeni mediji

• Twitter

• Uradna spletna stran
• Raziskovalec blokov

Analiza pretoka sredstev

etfindex:mc_etfindex_source Omejitev odgovornosti: Podatke zagotavlja cmc in se ne smejo obravnavati kot naložbeni nasveti.